Rein Therapeutics Inc (RNTX) Stock Analysis
Verdict: AVOID
Insider buying provides a floor, but a critical liquidity crunch and 0.39 current ratio make imminent dilution the primary price driver.
Investment score: 38/100
Analysis as of
Is Rein Therapeutics Inc stock worth reviewing? AI model thesis
RNTX is a high-risk microcap biotech with a failing balance sheet and no revenue. Despite strong insider support near $1.00, the high burn rate and 0.39 current ratio signal a high probability of share dilution within 90 days.
7-factor investment score
- Valuation: 30/100 (weight 20%)
- Financial Health: 10/100 (weight 15%)
- Technical Momentum: 25/100 (weight 15%)
- Earnings Quality: 35/100 (weight 15%)
- Insider Sentiment: 95/100 (weight 10%)
- Analyst Consensus: 60/100 (weight 10%)
- Risk-Adjusted Return: 30/100 (weight 15%)
Rein Therapeutics Inc opportunities and risks
What speaks for RNTX
- Concentrated Insider Buying
What speaks against RNTX
- Imminent Liquidity Exhaustion
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| RNTX | n/a | 0.0x | n/a | 0.0% | 0.0% | -54.0% |
| CADL | n/a | 0.0x | n/a | 0.0% | 0.0% | -10.8% |
| PEPG | n/a | 0.0x | n/a | 0.0% | 0.0% | -74.7% |
| ALDX | n/a | 0.0x | 1919339.4x | 0.0% | 0.0% | -25.2% |
| ATRA | n/a | 4.3x | n/a | 96.1% | -40.9% | -26.3% |
| HSTC | n/a | 53.3x | n/a | 71.9% | -107.6% | -5.1% |
| Peer median | n/a | 0.0x | n/a | 0.0% | 0.0% | -25.2% |
Frequently asked questions about Rein Therapeutics Inc (RNTX)
Is RNTX stock a good investment?
The cached TradeMates AI model rates Rein Therapeutics Inc as AVOID with an investment score of 38/100. RNTX is a high-risk microcap biotech with a failing balance sheet and no revenue. Despite strong insider support near $1.00, the high burn rate and 0.39 current ratio signal a high probability of share dilution within 90 days. This is algorithmic model output, not personal investment advice.
Is RNTX stock a buy?
The TradeMates model verdict for RNTX is AVOID with an investment score of 38/100. Treat this as a model signal to review, not a personal buy recommendation.